Edmond de Rothschild Investment Partners' Portfolio Company EOS imaging Raises close to EUR40 million in 4 times Oversubscribed IPO
Paris, France- 15 February 2012- Edmond de Rothschild Investment Partners announces that its portfolio company EOS imaging, which has developed the world's first 2D/3D imaging system dedicated to orthopaedic applications, has raised EUR38 million in a 4 times oversubscribed public offering of shares on the NYSE Euronext. Based on the IPO pricing, the company is valued at more than EUR120 million.
The success of this IPO is an acknowledgment of EOS imaging's outstanding technology and its large market potential. The funds will be used to support the commercial expansion of the company. Raphael Wisniewski, Edmond de Rothschild Investment Partners' representative on EOS imaging board comments: 'We are proud to have backed the team led by its CEO Marie Meynadier alongside high quality investors. We are pleased to see the strong support of the European public markets for this innovative medical technology company. This is another very positive signal for European startups overall.' Edmond de Rothschild Investment Partners has been the lead investor and the company's largest shareholder since 2005.
This IPO is the 2nd listing on a major public market for a company of its BioDiscovery 2 fund managed by Edmond de Rothschild Investment Partners. The BioDiscovery funds have now completed 8 trade sales and 9 IPOs, reflecting the excellent performance of this family of funds.
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently EUR960 million under management which is being invested primarily as life sciences venture capital and growth capital.
Its Life Sciences Team of eight professionals brings together over 55 years of experience in the Life Science industry and more than 90 years of private equity and venture capital experience. The team has EUR210 million under management through its Biodiscovery franchise comprising three funds raised in 2000, 2005 and 2008.
Edmond de Rothschild Investment Partners is an independently managed affiliate of La Compagnie Financière Edmond de Rothschild Banque. For more information please visit: www.edrip.fr.
About EOS imaging
The EOS imaging group designs, develops and markets EOS(R), a revolutionary and patented medical imaging system, based on technology that enabled Georges Charpak to win the Nobel Prize for Physics. The Group has obtained authorisation to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 42 sites and more than 150,000 imaging sessions, EOS(R) benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people including an R&D team of 21 engineers and recorded consolidated revenue of EUR4.8 million in 2010. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.
Further information about EOS imaging can be found at the following site: www.eos‐imaging.com.
Edmond de Rothschild Investment Partners
Raphael Wisniewski - 00 33  40 17 27 69